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Objectives: To assess whether familial non-medullary thyroid cancer (FNMTC) represents
an independent risk factor for increased aggressiveness of the tumor, as concern as
the clinical presentation and the long-term follow-up in respect of sporadic differentiated
thyroid cancer (SDTC).
Design: Retrospective study; 1976–2014.
Patients and Methods: Seventy-four FNMTC families (151 affected individuals): fam-
ily relationship and number of affected family members were evaluated. Clinical and
histopathological features and outcome were compared to that of 643 SDTC patients fol-
lowed in the same period according to the same institutional protocols. Median follow-up
was 57.7months (range 12–136) in FNMTC and 59.7 (range 15–94.6) in SDTC patients.
Results: Three cases occurred in 3 families and 2 cases in the other 71. F:M was 3.7:1 in
FNMTC and 4.3:1 in SDTC (NS). The family relationship was siblings in 62.2%. Mean age
at diagnosis was lower in FNMTC than in SDTC (p<0.005). Papillary/follicular histotype
distribution was similar (86%). Papillary tumors were more frequently multifocal in FNMTC
(p=0.004) and with lymph-node metastases (p=0.016). Disease-free survival (DFS) was
shorter in FNMTC vs. SDTC (p<0.0001) with 74.8 vs. 90.8% patients free of disease at
the last control (p<0.005). Three patients died in FNMTC group vs. 1 in SDTC (p=0.02).
Conclusion: Familial non-medullary thyroid cancer displays distinct characteristics as
earlier age of onset and increased aggressiveness at diagnosis and a higher rate of
persistent/recurrent disease and mortality with a shorter DFS in respect with SDTC.
FNMTC patients, therefore, should be followed accurately. As the specific gene (or genes)
responsible for susceptibility for FNMTC has not yet been identified, a low frequency
periodic screening of relatives DTC patients may be useful to identify FNMTC patients at
early stage of disease.
Keywords: thyroid, thyroid cancer, familial thyroid cancer, thyroid cancer prognosis, familial non-medullary thyroid
cancer
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Introduction
Familial non-medullary thyroid cancer (FNMTC) represents
approximately 3–7% of all thyroid cancers that originate from
thyroid follicular epithelial cells (1).
Since the genetic alterations responsible for this disease are not
known, FNMTC is defined as the condition in which two or more
first-degree relatives are affected by thyroid cancer in the absence
of a known familial syndrome.
However, due to the high prevalence of differentiated thyroid
carcinoma (DTC), it is estimated that when two members of the
same family are affected, there is a 53% probability that the disease
has a familial origin but also a 47% probability that it is sporadic.
When three or more family members are affected, the probability
rises to 99.9% (2).
As already mentioned, to be defined familial, FNMTC should
not represent the phenotypic expression of a genetic familial
syndrome. There are, in fact, familial cancer syndromes regarding
non-thyroid tumorswhere thyroid carcinomamay also be present.
These include theCowden syndrome (multiple hamartomas in the
skin and mucosa and cancers in various organs and tissues, such
as the breast, thyroid, and uterus), the familial adenomatous poly-
posis (FAP) characterized by multiple and diffuse adenomatous
polyps in the colon, osteomas, epidermoid cysts, desmoid tumors,
hamartomas of the upper digestive tract, congenital hypertrophy
of retinal pigment epithelium, hepatoblastoma, and the Carney
complex (pigmentation of the skin and mucous membranes,
mucosal lesions, and tumors of the endocrine glands, such as
pituitary and adrenal adenomas, Sertoli and Leydig cell tumors,
and thyroid carcinoma), the Werner syndrome (characterized
by premature aging, bilateral cataracts, gray hair, skin atrophy,
and cancer in different organs including the thyroid), and finally
syndromes in which thyroid cancer is associated with clear cell
renal carcinoma (3, 4).
Many studies suggest that FNMTC is a defined entity with
early cancer onset and aggressive features relative to sporadic
thyroid cancer but the topic remains controversial (5). The present
study aims to assess whether FNMTC represents a homogeneous
biological entity that is significantly different from sporadic differ-
entiated thyroid cancer (SDTC). In a continuous series of FNMTC
patients followed at our Thyroid Clinic we evaluated, the number
of affected family members, the modality of the cancer transmis-
sion, the onset characteristics (incidence for gender and age and
clinical presentation), histopathological features, and long-term
outcome. Data from FNMTC patients were compared to a control
group of SDTC patients.
Patients and Methods
We retrospectively analyzed a consecutive series of 4120 thy-
roidectomized DTC patients in the 1976–2014 period, all fol-
lowed at the Thyroid Clinic, Division of Endocrinology, Garibaldi
Medical Center in Catania, Italy.
Among this series, we identified 264 (6.4%) patients with a
positive family history that were classified FNMTC because at
least one first-degree relative was affected by confirmed thyroidal
cancer of follicular origin.
Only patients having all family members with FNMTC in
continuous follow-up in our Center were included: 151 patients
belonging to 74 families.
All patients underwent total thyroidectomy, with a central
and/or lateral-cervical lymph-node dissection in 53 cases (35.1%).
Tumors were staged according to the VII TNM edition (6): T
(the extent of the primary tumor) and N (regional lymph-node
metastases) were assessed on the basis of pathological exami-
nation, and M (distant metastases) according to the first post-
surgical 131I-whole-body scan (131I-WBS).
After surgery, radioiodine (1110–3700MBq) was administered
to 131/151 patients (86.7%) who met one or more of the sub-
sequent criteria: tumor size >1.0 cm, tumor extension to soft
tissues adjacent to the thyroid gland, multifocal tumor, and/or
nodalmetastases. Follow-upprocedures includedneckultrasound
and serum thyroglobulin (Tg) after either L-T4 withdrawal or
recombinant human TSH stimulation.
Persistent/recurrent disease was defined by one or more of
the following criteria: (1) serum Tg, either under suppressive
L-T4 therapy or after TSH stimulation, at detectable levels, as
defined by the assay sensitivity limits at the time of measure-
ment; (2) evidence of metastatic lymph nodes identified at neck
ultrasound and confirmed by FNAB with Tg measurement in the
aspirate washout; (3) positive 131I-WBS. Computed tomography,
magnetic resonance imaging, bone scan, and positron emission
tomography were performed when appropriate in patients with
persistent/recurrent disease.
Data in FNMTC patients were compared to those obtained
in a control group of 643 SDTC patients matched at 1:4 ratio
for the long-term follow-up. In the control group, post-operative
radioiodine treatment was administrated in 390 cases (60.6%).
Median follow-up was 57.7months (range 12–136) in FNMTC
and 59.7 (range 15–94.6) in SDTC patients.
Ethical approval
All procedures involving human participants were in accordance
with the ethical standards of institutional research committee and
with theHelsinki declaration as revised in 2013. Informed consent
of the present retrospective study was waived.
Statistical Analysis
Quantitative data were compared using the t-test, and qualitative
data were compared by the chi-square analysis. The disease-free
survival (DFS) curves were determined by Kaplan–Meier curves.
p values<0.05 were considered statistically significant.
Results
Familial Characteristics and the Mode of
Transmission of Tumors in Patients with FNMTC
Seventy-one (95.9%) of the 74 families with FNMTC had two
affected family members, and three families patients (4.1%) had
three affected family members. The transmission of the disease
was maternal in 40 cases from 20 families and paternal in 11 cases
from 5 families. In 94 cases (47 families), the disease was present
in brothers and sisters. In six cases (two families) in addition
to the first-degree also a second-degree relative with FNMTC
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TABLE 1 | Family relationship of patients with FNMTC.
Families (74) n.% Patients (151) n.%
Paternal 5 (6:8) 11 (7:3)
Maternal 20 (27:0) 40 (26:5)
Sibling (brother-sister) 47 (63:5) 94 (62:2)
Other 2 (2:7) 6 (4:0)
was identified (two sisters and their maternal aunt and brother,
sister, and her daughter affected in the two families, respectively)
(Table 1).
Characteristics of Patients with FNMCT and
SDTC
Table 2 shows the characteristics of patients with FNMTC and
SDTC.
Of the 151 FNMTC patients studied, 119 (78.8%) were females
(F) and 32 (21.2%) were males (M), with an F/M ratio of 3.7/1;
in the control group (643 patients with SDTC), there were 521 F
(81.0%) 122 M (19.0%), with an F/M ratio of 4.3/1 (p= 0.57).
The median age at diagnosis was 45.4 13.5 years for FNMTC
(range 17.1–81.5) and 48.0 13.7 years (range 16.8–82.6) for
SDTC (p< 0.005).
TNM Staging and Histopathological Features of
Thyroid Carcinoma in FNMTC and SDTC
Table 3 shows the distribution of histological types in the two
groups studied.
The ratio between the papillary or follicular histological type
was in favor of the papillary and its variant in familial compared
to sporadic thyroid carcinoma, which showed no statistically
significant difference (11.6/1 vs. 14.7/1, respectively).
Table 4 shows the histopathologic features of tumors in both
groups, including size, multifocality, bilaterality, and extrathy-
roidal extension.
In patients with FNMTC, the medium tumor size was
1.5 1.2 cm (range 0.1–7.0). In addition, the tumor was mul-
tifocal in 69 cases (45.7%), bilateral in 48 (31.7%), and with
extrathyroidal extension in 33 cases (21.8%).
In the control group, tumor medium size was 1.5 1.3 cm
(range 0.4–6.0), multifocal in 214 cases (33.2%), bilateral in 158
(24.5%), with extrathyroidal extension in 126 (19.6%).
The percentage of multifocal tumors in patients with
FNMTC compared to patients with SDTC was highly significant
(p= 0.004).
No significant differences were found regarding bilateral
involvement or extrathyroidal extension.
Table 5 shows the TNM staging of FNMTC and SDTC. Any
significant differences among stages were observed in the two
groups of patients (Table 6).
In FNMTC, we found a lower proportion of microcarcinomas
than in sporadic thyroid cancer (60/151 vs. 316/643, respectively,
p= 0.038). No significant difference was found among the vari-
ous groups’ pT, while there was a more significant presence of
lymph-node metastases in familial tumors (40/151 vs. 113/643,
respectively, p= 0.016).
TABLE 2 | Characteristics of FNMTC and SDTC patients.
FNMTC (151) SDTC (643)
Gender (F/M) ratio 119/32 521/122
Age (years) 3.7/1 4.3/1
MeanSD 45.413.5 4813.7*
range 17.1–81.5 16.8–82.6
*p<0.005.
TABLE 3 | Histotypes of FNMTC and SDTC.
Histotype FNTMC (151) n.% SDTC (643) n.%
Papillary classic and follicular variant 130 (86:1) 558 (86:8)
Diffuse sclerosing variant 4 (2:6) 15 (2:3)
Tall cell variant 3 (2:0) 29 (4:5)
Papillary cistyc variant 1 (0:7) 0 (0)
Follicular 10 (6:6) 23 (3:6)
Hurtle Cell 3 (2:0) 18 (2:8)
TABLE 4 | Histopathologic features of FNMTC and SDTC.
FNMTC (151) SDTC (643)
Tumor size (cm) 1.51.2 1.51.3
MeanSD range 0.1–7.0 0.4–6.0
Multifocality (%) 69 (45.7) 214 (33.2)*
Bilaterality (%) 48 (31.7) 158 (24.5)
Extrathyroidal extension (%) 33 (21.8) 126 (19.6)
*p=0.004.
TABLE 5 | TNM (VII ed.) staging of FNMTC and SDTC.
FNMTC (151) n.% SDTC (643) n.%
pT1 86 (57:0) 418 (65:0)
pT2 13 (8:6) 79 (12:3)
pT3 38 (25:2) 144 (22:4)
pT4 1 (0:6) 2 (0:3)
pTx 13 (8:6) 0 (0)
N1 40 (26:4) 113 (17:5)*
M1 4 (2:6) 8 (1:2)
*p=0.016.
TABLE 6 | TNM staging (VII ed.) of FNMTC and SDTC.
FNMTC (151) n% SDTC (643) n%
Stage I 111 (73:5) 486 (75:6)
Stage II 8 (5:3) 43 (6:7)
Stage III 22 (14:6) 94 (14:6)
Stage IV 7 (4:6) 20 (3:1)
Not evaluable 3 (2:0) 0 (0)
Outcome and Prognosis
We evaluated, in both groups of tumors, the DFS and the number
of patients without persistent/recurrent disease at the last control
visit.
As shown in Figure 1, the DFS of patients with FNMTC
[median 33.8months (range 6–136)] was significantly shorter
(p< 0.0001) than that observed in patients from the control group
Frontiers in Endocrinology | www.frontiersin.org August 2015 | Volume 6 | Article 1173
Tavarelli et al. Familial non-medullary thyroid cancer
FIGURE 1 | Disease-free survival in FNMTC vs. SDTC patients.
[median 55.9months (range 6–95)]. In FNMTC patients, at the
last control visit, we observed a lower percentage of cases free
from disease (p< 0.0001) than we observed in the control group
(Figure 2). In particular, 113/151 (74.8%) FNMTC patients were
disease free and 38 (25.2%) showed persistent disease. Three
patients died for the disease. Concerning SDTC patients, 584
(90.8%) were disease free and 59 (9.2%) had persistent disease at
the last control visit; 1 patient died (Table 7).
Concerning familial microcarcinomas (60 patients), we did not
find any significant differences with respect to the control group
(316 patients), either regarding theDFS (6 recurrences in FNMTC
vs. 14 in SDTC) or the percentage of disease-free patients at the last
control visit (persistence of disease in 3 FNMTC patients vs. 13 in
SDTC).
Regarding familial microcarcinomas, which according to the
TNM system can be classified as T1a N0/NXM0 (29 cases), there
was no significant difference for DFS (p= 0.07) or for the per-
centage of disease-free patients at the last control visit (p= 0.23)
compared to patients with SDTC (189 cases).
Familial non-medullary thyroid cancer with maternal trans-
mission was not more aggressive than other FNMTCs (p= 0.23
for DFS and p= 0.28 for the percentage of patients free of dis-
ease at the end of follow-up); on the contrary, we found that
DFS was significantly longer (p= 0.038) in patients in whom
the family relationship was brother–sister than in other relation-
ships [62.6months (range 6–341months) and 12months (range
6–222months), respectively] (Figure 3), with a greater percentage
of patients free from disease at the last control visit (p< 0.005)
(Figure 4).
FIGURE 2 | Disease-free status at last control visit in FNMTC vs. SDTC
patients.
TABLE 7 | Disease status al last control visit in FNMTC and SDTC patients.
FNMTC (151) n.% SDTC (643) n.%
Disease free 113 (74:8) 584 (90:8)*
Persistent disease 38 (25:2) 59 (9:2)
Lymphnodes 8 (21:1) 10 (16:9)
Distant metastases 8 (21:1) 12 (20:3)
Local and distant metastases 4 (10:5) 0 (0)
Only detectable thyroglobulin 18 (47:3) 37 (62:8)
*p<0.001.
Discussion
Familial non-medullary thyroid cancer is a rare entity that
accounts for approximately 3.3–6.9% of all thyroid cancer
cases (7).
The clinical behavior of FNMTC is still controversial, including
the rate of persistence/recurrence and patient survival compared
to sporadic thyroid cancer. In our study, the most frequent mode
of cancer transmission was between brothers and sisters (62.2%),
followed bymaternal transmission (26.5%) and paternal transmis-
sion (7.3%) and in two families (4%) in addition to the first-degree
also a second-degree relative with FNMTC was identified. There
are few data regarding the mode of transmission in the literature,
with the exception of the study by Rumianteseva et al. in which, in
a series of 48 patients with FNMTC belonging to 24 families, was
found a greater frequency of maternal transmission (75.0%) (8).
In our study, FNMTC is diagnosed earlier than SDTC
(45.4 13.5 vs. 48.0 13.7 years to diagnosis). The early onset
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FIGURE 3 | Disease-free survival in FNMTC patients with
brother/sister tumor transmission vs. patients with other relationship.
FIGURE 4 | Cured patients at last control visit in FNMTC with
brother/sister tumor transmission vs. patients with other relationship.
of FNMTC may be due to an early diagnosis because of the
familial nature of the disease or to the phenomenon of antic-
ipation typical of familial cancers which, according Capezzone
et al. (9, 10), derives from an alteration of the telomere–telomerase
complex, which is characterized by short telomeres and increased
amplification and expression of the gene coding for telomerase
reverse transcriptase (hTERT) (11). This finding and the more
aggressive presentation at diagnosis agree with Linch’s hypothesis
that FNMTC tends to appear earlier inmembers of families where
the transmission involves first-degree relatives. Other studies have
shown similar findings: in the study by Loh (12), FNMTC was
diagnosed 10 years earlier than sporadic thyroid carcinoma; sim-
ilar results were recently reported by different authors (13–15).
According to Mc Donald, age at presentation in FNMTC patients
was not different when compared to the sporadic form (16).
From a histological viewpoint, FNMTC is indistinguishable
from sporadic forms of well-DTC, and these data were con-
firmed in our study. Regarding the histopathological features of
the tumor, we found a greater number of multifocal tumors in
FNMTC compared to the control group. This feature, as reported
in many studies, constitutes one of the peculiarities of this form of
cancer. The largest study regarding the characteristics of patients
with FNMTC is from Japan. Uchino et al. examined 6,458 patients
and identified 258 cases of FNMTC, with a median age at diag-
nosis of 49 years, and although the tumor size at diagnosis was
not different compared to sporadic cancers, multifocality was
observed more frequently (42 vs. 30%) (17). According to Clark
et al., FNMTC is multifocal in 93% and bilateral in 43% of cases
while in sporadic thyroid cancer, multifocality is observed in
20–32% of cases and bilateral foci are detected in 19% (1).
Similar data were found by Alsanea (18) and Ito (19), who
showed that FNMTC was multifocal in 46 and 38%, respectively.
Other recent studies confirmed these findings (13, 14, 20, 21).
In our study, FNMTCmore frequently exhibited nodal involve-
ment at diagnosis compared to sporadic forms, although we did
not observe a major incidence of extrathyroidal tumors.
This is in agreement with other data in the literature: in 1995,
Grossman documented an incidence of lymph-node metastases
at diagnosis in 57% of patients with FNMTC vs. 38% of patients
with sporadic thyroid carcinoma (22). Similar data were reported
in the study of Alsanea (18) and Mazeh (13), but these data were
not confirmed by Ito (19), Uchino (17), and Moses (15).
Regarding clinical evolution and prognosis, we found a signif-
icant reduction in DFS and a worse prognosis in FNMTC than
in SDTC. In 1995, Grossman documented a recurrence rate of
50% in patients with FNMTC vs. 15% in patients with SDTC (22).
Alsanea confirms these data and reports a lower rate of survival
in patients with FNMTC, with a recurrence of 44 vs. 17% in the
control group (18). In Uchino et al. series, FNMTCs showed no
significant increase of local invasion or lymph-node metastases
at diagnosis compared to SDTC patients but had a significant
recurrence rate (16.3 vs. 9.6% p= 0.0005) with a DFS significantly
shorter (p= 0.004) (17).
Patients with differentiated thyroid microcarcinoma typically
have an excellent prognosis. Lupoli et al., evaluating a series of
tumors in patients with familial and sporadic microcarcinoma,
showed that in familial forms, the tumor was multifocal in 71%
of cases (vs. 19% in sporadic forms) and bilateral in 43% (vs.
19%), with high frequency of lymph-nodemetastases (57 vs. 28%)
and vascular invasion (43 vs. 5%). The recurrence rate in these
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patients was significantly higher (43 vs. 5%), and one patient died
ofwidespreadmetastasis (23). This study shows that the aggressive
nature of FNMTC persists in very small tumors. Others studies
do not confirm these findings (24, 25). According to the data
emerging from our study, 60 FNMTC patients with microcar-
cinoma did not show a significant difference compared to 316
patients in the microcarcinoma group control, either regarding
DFS or the percentage of patients free from disease at last control
visit.
It is now widely recognized that familial cancers are more
aggressive than sporadic ones, even if it is difficult to separate the
two forms, especially when only two family members are affected;
in fact, in this case, there is a 69% probability that the cancer is
familial, but it might also be a sporadic thyroid cancer (26).
In families where three or more family members are affected
and where genetic alteration is almost certain, the high aggres-
siveness of the tumor is clearly demonstrated by the prognosis
and the final outcome, as showed in the study by Triponez et al.
(2). He showed that survival is reduced when the diagnosis of
FNMCT is made before the family pathology is recognized com-
pared to patients who have a known family history of thyroid
cancer.
This suggests that early diagnosis and treatment are very impor-
tant to improve the quality of life and survival of patients with
FNMTC. Therefore, pre-screening is recommended in patients
who have family members with FNMTC (approximately when
they are 10 years younger than the affected family members) (1).
A recent meta-analysis of Wang et al. reporting 12 studies with
a total of 12,741 patients confirmed that FNMTC shows more
aggressive biological behaviorswith younger age at diagnosis, high
risk of multifocal, bilateral, extrathyroidal tumor, and lymphnode
metastases at diagnosis and has an increased rate of recurrence
and decreased DFS in comparison to SDTC (27).
Our study also showed that the siblings of a family member
with FNMTC have a better prognosis than off-spring of parents
with FNMTC, and these data were similar to that reported by
Park et al. (14).
Regarding the type of treatment, all patients with FNMTC
should undergo total thyroidectomy to avoid, in genetically pre-
disposed patients, the proliferation of residual tumor tissue. Due
also to the high incidence of lymph-node metastasis to the central
neck (level VI) at the time of diagnosis, central lymph-node
dissection should be considered for these patients. Involvement
of lateral neck cervical lymph nodes should be assessed pre-
operatively.
Furthermore, because FNMTC has a high recurrence rate,
which is an important cause of reduced patient survival, many
experts recommend that all patients should undergo I131
radioactive iodine treatment and post-surgery L-T4 suppressive
therapy.
At present, FNMTC follow-up guidelines are not available, but
due to the points discussed above, surgical and post-operative
treatment and follow-up should be planned because of the aggres-
siveness of these tumors. It will be useful to separate these patients,
even if belonging to the same class of risk, according to the
presence or absence of familial cases. Therefore, the majority of
patients should undergo radioiodine ablation independently of
tumor size to achieve complete ablation of residual thyroid tissue
(1, 17).
The genetic basis of FMNTC remains unknown, but it is
believed that the genetic alterations are transmitted as an autoso-
mal dominant incomplete penetrance and variable expressivity.
Some of the chromosomal loci identified could play a role in
the development of cancer, but none of them seem sensitive to
propose a genetic screening test for high risk-families.
In conclusion, our study showed that:
1. Familial non-medullary thyroid cancer is found more fre-
quently in siblings.
2. Familial non-medullary thyroid cancer is diagnosed at an ear-
lier age than sporadic thyroid carcinoma; it is less frequently
a microcarcinoma but more often shows multifocal foci and
lymph-node metastases at diagnosis.
3. Familial non-medullary thyroid cancer has a worse prognosis
than SDTC, with a disease-free time significantly lower than
that observed in patients with sporadic thyroid cancer.
4. Siblings of individuals with FNMTC have a better prognosis
than FNMTC with other relationships ones.
Further studies are still needed to define the best management
for FNMTC. Because there is not a genetic test to identify at-risk
patients, an early screening of patients who have family members
with FNMTC is essential to identify the tumor at an early stage.
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